Media Advisory

Tuesday, October 15, 2024

NIH and FDA leaders call for innovation in development of smoking cessation treatments

Commentary emphasizes that engagement across stakeholders is critical to accelerate smoking cessation and reduce smoking-related disease and death.

If you or someone you know is struggling or in crisis, help is available. Call or text 988 or chat at . To learn how to get support for mental health, drug or alcohol conditions, visit . If you are ready to locate a treatment facility or provider, you can go directly to  or call 800-662-HELP (4357).

What

In a new commentary in the Annals of Internal Medicine, leaders at the 2023 ÃÛÑ¿´«Ã½ (NIH) and U.S. Food and Drug Administration (FDA) highlight recommendations and opportunities to promote innovation in research and development of smoking cessation therapies, for which there is an urgent need. The authors provide an update on regulatory pathways for smoking cessation treatment, as well as an overview of innovative therapeutic targets, research gaps, and opportunities. They emphasize that active engagement across clinicians, academia, industry, public health, patient advocacy groups, and other stakeholders is critical.

Cigarette smoking kills nearly 500,000 Americans each year, and over 28 million adults currently smoke in the United States. Though most adults who smoke report that they want to quit, only 31% of those interested in quitting receive counseling and/or medications, and less than 8% effectively quit each year.

The commentary authors highlight recommendations to address these gaps, including from . To spark greater innovation in the development of smoking cessation products, the authors highlight the importance of considering meaningful study endpoints in addition to abstinence in smoking cessation trials. For instance, clinically meaningful reductions in smoking, especially if such reductions increase the probability of eventual cessation.

The authors also emphasize the urgent need for greater research on e-cigarettes, including on long-term health outcomes and rigorous toxicology studies. In addition, they discuss ongoing initiatives at NIH and FDA that aim to facilitate innovative research on smoking cessation, including among groups that have been historically underrepresented in research trials.

The commentary is publishing in advance of an , which is being held on Monday, Oct. 21, from 9 a.m. to 4:30 p.m. EDT. .

Article

H Warraich, et al. . Annals of Internal Medicine. DOI: 10.7326/ANNALS-24-02318 (2024).

Who

  • Wilson Compton, M.D., deputy director, NIH’s National Institute on Drug Abuse
  • Brian King, Ph.D., director of the FDA’s Center for Tobacco Products

About the National Institute on Drug Abuse (NIDA): NIDA is a component of the 2023 ÃÛÑ¿´«Ã½, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit .
Ìý

About the 2023 ÃÛÑ¿´«Ã½ (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

###